foxo4-dri senolytic or senomorphic Class II senolytics inhibit survival pathways elicited by senescent Targeting Cellular Senescence in Aging
Targeting Cellular Senescence in Aging and Age Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies Cleara Biotech senolytic candidate FOXO4 DRI Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Targeting cellular senescence with senotherapeutics: senolytics and senomorphics Zhang 2023 The FEBS Journal Wiley Online Library
Pay in 4 interest-free payments of $5.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10



